10-Q: Cardiff Oncology Reports Increased Losses Amid Promising Clinical Trial Progress for Onvansertib

Cardiff Oncology's latest quarterly report reveals a significant increase in net loss and cash burn, while highlighting positive clinical data for its lead asset, onvansertib, across multiple cancer indications and securing a new patent.

Summary

• Net loss for the six months ended June 30, 2025, increased to $27.377 million, up from $21.789 million in the same period of 2024.
• Research and development expenses rose by $4.556 million to $22.057 million for the six months ended June 30, 2025, primarily due to costs associated with the CRDF-004 clinical trial and other clinical programs.
• Selling, general and administrative expenses increased by $0.987 million to $7.332 million for the six months ended June 30, 2025, driven by professional fees and new stock option grants.
• Cash and cash equivalents decreased to $10.784 million as of June 30, 2025, from $51.470 million at December 31, 2024, though short-term investments increased, resulting in total cash, cash equivalents, and short-term investments of $71.0 million.
• Net cash used in operating activities for the six months ended June 30, 2025, was $21.122 million, an increase from $16.970 million in the prior year period.
• Enrollment for the CRDF-004 Phase 2 randomized clinical trial in first-line RAS-mutated metastatic colorectal cancer (mCRC) was completed in April 2025, with initial data showing a 57% objective response rate (ORR) for all onvansertib patients (12 of 21) compared to 33% for the control arm (3 of 9).
• Positive data from the TROV-054 Phase 1b/2 trial in second-line KRAS-mutated mCRC showed an ORR of 29% and median progression-free survival (mPFS) of 9.3 months across all evaluable patients, significantly exceeding historical controls (5-13% ORR, ~4.5-6.7 months mPFS).
• A subgroup analysis from TROV-054 indicated that bevacizumab-naive patients (n=15) achieved an ORR of 73% and mPFS of 15 months.
• A new investigator-initiated Phase 1b/2 trial for metastatic pancreatic ductal adenocarcinoma (mPDAC) combining onvansertib with NALIRIFOX is now open for enrollment.
• Positive data from the Phase 1b trial in metastatic triple negative breast cancer (mTNBC) presented in June 2025 at ASCO demonstrated a 40% ORR at the recommended Phase 2 dose (RP2D) of 18mg/m2 (n=10).
• A second patent (U.S. patent No. 12,263,173) was issued on April 23, 2025, for the treatment of mCRC in bev-naive patients, with an expected expiration date no earlier than 2043.
• Roger Sidhu, M.D., was appointed Chief Medical Officer on June 17, 2025.

Sentiment

Score: 6

Explanation: While financial results show increased losses and cash burn, the clinical trial data for onvansertib across multiple indications is promising and exceeds historical controls in key areas. The FDA's agreement on an accelerated approval pathway for mCRC and the new patent issuance are significant positives. The company also has a reasonable cash runway into Q1 2027. The sentiment is cautiously positive, balancing strong clinical progress against the financial burn and future capital needs.

Positives

• Enrollment for the pivotal CRDF-004 Phase 2 trial in first-line RAS-mutated mCRC was completed in April 2025, moving closer to potential registrational studies.
• Initial CRDF-004 data showed a higher objective response rate (ORR) for onvansertib in combination with standard-of-care (57%) compared to standard-of-care alone (33%), indicating potential efficacy.
• Onvansertib in combination with chemo/bevacizumab was well-tolerated in CRDF-004, with no major or unexpected toxicities observed.
• The FDA has agreed to a seamless trial design for CRDF-005 (Phase 3), allowing an interim ORR endpoint for accelerated approval, which could expedite market entry.
• TROV-054 trial data demonstrated superior ORR (29%) and median progression-free survival (9.3 months) compared to historical controls (5-13% ORR, 4.5-6.7 months mPFS) in KRAS-mutated mCRC.
• The bevacizumab-naive subgroup in TROV-054 showed exceptional results with a 73% ORR and 15 months mPFS, highlighting a potentially highly responsive patient population.
• New investigator-initiated trials are advancing onvansertib into additional indications like mPDAC and mTNBC, expanding the drug's potential market.
• Positive Phase 1b data for onvansertib in combination with paclitaxel in mTNBC, showing a 40% ORR, supports further development in this challenging cancer.
• The issuance of a new U.S. patent for mCRC treatment in bev-naive patients extends intellectual property protection until at least 2043, strengthening the company's market position.
• The company believes it has sufficient cash to meet funding requirements for at least the next 12 months and projects funding into the first quarter of 2027, providing a reasonable financial runway.

Negatives

• Net loss significantly increased to $27.377 million for the six months ended June 30, 2025, compared to $21.789 million in the prior year period.
• Cash and cash equivalents decreased substantially from $51.470 million at December 31, 2024, to $10.784 million at June 30, 2025, indicating a high cash burn rate.
• Net cash used in operating activities increased to $21.122 million for the six months ended June 30, 2025, from $16.970 million in the same period of 2024.
• Royalty revenues decreased to $0.2 million for the six months ended June 30, 2025, from $0.4 million in the prior year period.
• The company expects to continue incurring losses and will require additional capital for future clinical trial programs and operations.
• Net cash provided by financing activities was only $3 thousand for the six months ended June 30, 2025, a significant drop from $2.165 million in the prior year, indicating less capital raised from equity or options.

Risks

• The company has incurred net losses since its inception and has negative operating cash flows, which are expected to continue for the foreseeable future.
• Additional funding will be required to further advance clinical trial programs and support operations, and there is no certainty that such funding will be available on acceptable terms, or at all.
• Issuing equity securities to raise additional funds may result in significant dilution for existing stockholders.
• Drug development efforts are in early stages, and there is high uncertainty regarding the costs, time to completion, and timing/amount of future revenues from drug candidates.
• The risk of completion for any program is high due to uncertainties in developing new drug candidates, including long clinical testing durations, stringent clinical trial protocols, extended regulatory approval cycles, and competition from organizations with significantly greater resources.
• Litigation is subject to inherent uncertainties, and adverse results in matters that may arise could harm the company's business or financial condition.

Future Outlook

The company expects to continue incurring losses and will require additional capital to further advance its clinical trial programs and support other operations. While it believes it has sufficient cash to meet funding requirements for at least the next 12 months, current projections indicate capital resources are sufficient to fund operations into the first quarter of 2027. The company plans to initiate CRDF-005, a Phase 3 randomized trial with registrational intent, contingent upon the results of CRDF-004, with the FDA having agreed to a seamless trial design for accelerated approval based on ORR and duration of response, followed by PFS and overall survival for full approval.

Management Comments

• Management believes the company has sufficient cash to meet its funding requirements for at least the next 12 months following the issuance date of these financial statements.
• Management expects to continue to incur losses and require additional capital to further advance clinical trial programs and support other operations for the foreseeable future.
• Management does not expect that disclosure controls and procedures will prevent or detect all errors and fraud, but they are designed to provide reasonable assurance of achieving their objectives.

Industry Context

Cardiff Oncology operates in the highly competitive and rapidly changing clinical-stage biotechnology sector, focusing on oncology. Its lead asset, onvansertib, targets PLK1 inhibition, a well-validated oncology drug target. The company's strategy of combining onvansertib with standard-of-care therapeutics aligns with a common industry trend to improve efficacy and overcome treatment resistance. The focus on RAS-mutated mCRC, mPDAC, SCLC, and mTNBC addresses areas of significant unmet medical need. The FDA's agreement on an accelerated approval pathway for mCRC highlights regulatory support for novel therapies in this space, potentially allowing for faster market entry compared to traditional pathways. The company's intellectual property strategy, including new patent issuances, is crucial for protecting its innovations in a competitive landscape.

Comparison to Industry Standards

• In the TROV-054 Phase 1b/2 trial for KRAS-mutated mCRC, onvansertib in combination with FOLFIRI and bevacizumab achieved an Objective Response Rate (ORR) of 29% and a median Progression-Free Survival (mPFS) of 9.3 months across all evaluable patients. This compares favorably to historical control trials of different drug combinations, including the standard-of-care (SoC) of FOLFIRI with bevacizumab, which have shown ORR of 5-13% and mPFS of approximately 4.5-6.7 months in similar patient populations.
• Specifically, the bevacizumab-naive subgroup (n=15) in TROV-054 demonstrated an ORR of 73% and mPFS of 15 months, which is significantly above historical controls for this patient segment.
• Initial results from the CRDF-004 Phase 2 trial in first-line RAS-mutated mCRC showed a 57% ORR for all onvansertib patients (12 of 21) compared to 33% for the control arm (3 of 9), suggesting a substantial improvement over SoC alone, though this is from an ongoing trial with a small control group.

Management Changes

Legal Proceedings

• Management believes that there are no claims against the company which could result in a material adverse effect on the company's business or financial condition as of the date of this report.

Stakeholder Impact

• Shareholders: Potential for dilution if future capital raises involve equity issuance; potential for significant value creation if clinical trials continue to show positive results and lead to regulatory approvals.
• Employees: Continued employment and potential for stock-based compensation, with new key hires in R&D and clinical operations.
• Patients: Potential for novel and more effective treatment options for various cancers, particularly RAS-mutated mCRC, KRAS-mutated mCRC, mPDAC, SCLC, and mTNBC.
• Creditors: Impacted by the company's ongoing net losses and reliance on future capital raises, though current liquidity is deemed sufficient for the next 12 months.
• Suppliers/Partners: Continued engagement for clinical trials, outside services, and lab supplies, as R&D expenses are increasing.

Next Steps

• Initiate CRDF-005, a Phase 3 randomized trial with registrational intent, contingent upon the results of CRDF-004.
• Continue enrollment for the investigator-initiated mPDAC Phase 1b/2 trial of onvansertib in combination with NALIRIFOX.
• Continue enrollment for the single-arm, two-stage, Phase 2 trial of onvansertib monotherapy in patients with relapsed SCLC.
• Further exploration of the combination of onvansertib plus paclitaxel for the treatment of mTNBC based on positive Phase 1b data.

Key Dates

Recommendation

While Cardiff Oncology's clinical data for onvansertib, particularly in mCRC, shows promising efficacy compared to historical controls and has received favorable FDA guidance for accelerated approval, the company's financial position is deteriorating with increasing net losses and cash burn. The current cash runway into Q1 2027 provides some buffer, but the explicit need for future capital raises introduces significant dilution risk. A 'Hold' recommendation reflects the balance between the strong clinical upside potential and the substantial financial risks and uncertainties associated with a clinical-stage biotech company that will require further funding.

Keywords

Oncology, Biotechnology, Clinical-stage, PLK1 inhibitor, Onvansertib, Metastatic colorectal cancer, mCRC, RAS-mutated, KRAS-mutated, Metastatic pancreatic ductal adenocarcinoma, mPDAC, Small cell lung cancer, SCLC, Metastatic triple negative breast cancer, mTNBC, Clinical trials, Drug development, SEC filing, 10-Q, Financial results, Cash flow, Research and development, Intellectual property, Patent, Corporate governance